Adicet Bio (ACET) has shared an announcement.
Adicet Bio, Inc. has received FDA clearance for its Investigational New Drug application for ADI-270, aimed at treating relapsed/refractory renal cell carcinoma. The company is set to begin a Phase 1 trial in the latter half of 2024 to evaluate the safety and effectiveness of the therapy, with preliminary results expected in the first half of 2025. ADI-270 is an innovative “off-the-shelf” CAR T cell therapy, and the upcoming trial will explore its potential as a monotherapy for adults with this challenging form of cancer.
For an in-depth examination of ACET stock, go to TipRanks’ Stock Analysis page.
